SELective Defunctioning Stoma Approach in Low Anterior Resection for Rectal Cancer (SELSA): a Prospective Study With a Nested Randomised Clinical Trial
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 212
- 试验地点
- 1
- 主要终点
- textbook outcome; stoma-free survival at two years without major LARS
研究概览
简要总结
The goal of this observational trial with a nested randomized controlled trial is to investigate a selective approach of defunctioning stoma in low anterior resection in rectal cancer patients. The primary outcome is a hybrid so-called textbook outcome; stoma-free survival at two years without major LARS, reflecting a functionally appropriate outcome after low anterior resection for rectal cancer. Secondary outcomes include anastomotic leakage, postoperative mortality, reinterventions, stoma-related complications, quality of life measures, LARS, and permanent stoma rate up to two years after index surgery.
详细描述
Systematic use of defunctioning stoma after low anterior resection for rectal cancer has been shown to reduce symptomatic anastomotic leakage and associated interventions. However, accumulating data suggest that this comes at the price of worse bowel dysfunction, a higher rate of permanent stomas and kidney injury. We aim to study whether a selective strategy of defunctioning stoma use might lead to fewer adverse consequences, while still being safe for patients.
This is a multicentre international prospective trial including a non-blinded randomised clinical trial. All patients with a primary rectal cancer planned for low anterior resection with colorectal or coloanal anastomosis are eligible. Patients enter a prospective observational study, in which a randomised clinical trial is nested. Patients eligible for randomisation are aged below 80 years, have an American Society of Anesthesiologists' fitness grade I or II, have no unresected distant disease, and have a predicted lower risk of anastomotic leakage. Patients will be randomised 1:1 to either an experimental arm with no defunctioning stoma or to a control arm with a defunctioning stoma. The randomisation is computer-generated with a concealed sequence and stratified by participating hospital and radiotherapy use. The main outcome is the composite measure of 2-year stoma-free survival without major low anterior resection syndrome (LARS). Secondary outcomes include anastomotic leakage, postoperative mortality, reinterventions, stoma-related complications, quality of life measures, LARS, and permanent stoma rate up to two years after index surgery. To be able to state superiority of any study arm regarding the main outcome, with 90% statistical power and assuming 25% attrition, we aim to enrol 212 patients.
This study has been approved by Ethical Review Authority in Sweden (2023-04347-01) and seeks permission in Norway and Danmark, respectively. The results will be disseminated through patient associations, popular science, the broader medical community, and conventional scientific channels.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adult patients with rectal cancer planned for a low anterior resection with anastomosis by TME with any surgical approach
- •Additional inclusion criteria for randomised part of the study:
- •Patients aged less than 80 years
- •Patients with American Society of Anesthetists' (ASA) fitness grade I or II as determined by the anaesthesiologist or the surgeon
- •Patients without clear radiological signs of distant disease before rectal cancer surgery (previous metastatic surgery is no exclusion criterion)
- •Anastomotic leak risk score of 0-1
- •Willingness to be randomised
排除标准
- •Insufficient command of Swedish, Norwegian, Danish or English to understand questionnaires or consent
- •Emergency rectal resection (tumour resection due to large bowel obstruction, perforation, etc)
- •Pregnancy or breastfeeding Additional exclusion criteria for randomised part of the study
- •Previous pelvic irradiation (due to e.g. gynaecological or urological cancer)
- •Preoperative tumour perforation or pelvic sepsis
- •Beyond TME surgery and/or concurrent resection of other organ
- •Concurrent corticosteroid treatment (prednisone-equivalent dosage ≥10 mg daily)
- •Planned postoperative chemotherapy
- •Smoking not completely ceased four weeks before surgery
- •Excessive alcohol consumption with social and medical consequences (as judged by the surgeon in charge) Intraoperative exclusion criteria for randomised part of the study
- •>2 staple firings for rectal transection
- •Intraoperative blood loss ≥250 ml for minimally invasive surgery
- •Intraoperative blood loss ≥500 ml for open or converted surgery
- •More than one intraabdominal anastomosis performed
- •Incomplete doughnuts
- •Air-leak test positive
- •Any significant intraoperative adverse event at the discretion of the operating surgeon (e.g. ureterotomy, bowel or tumour perforation, major medical event - pulmonary embolism, cardiac arrhythmia) (Gawria, 2022)
- •TME with anastomosis ultimately not done
结局指标
主要结局
textbook outcome; stoma-free survival at two years without major LARS
时间窗: 2 year
extant stoma, alive, and a LARS score at 30 or lesn has stabilised as well for those without a stoma in situ. no extant stoma, alive, and a LARS score at 30 or less at the time point two years after the anterior resection.
次要结局
- Length of hospital stay(until discharge within 90 days)
- Postoperative mortality(3 months)
- Quality of Recovery-15 Swedish (QoR15swe)(1 month)
- Adjuvant chemotherapy for high-risk patients(12 months)
- Recurrence (local and distant)(36 and 60 months)
- Stoma in situ(24 months)
- Major Low Anterior Resection Syndrome(12 and 24 months)
- Stay out of hospital(24 months)
- Anastomotic leakage(1,3,12 and 24 months)
- Complications(1,3,12 and 24 months)
- Quality of life by European Organization for Research and Treatment of Cancer- ColoRectal 29 (EORTC-CR29)(12 and 24 months)
- Renal function(12 and 24 months)
- Overall survival(36 and 60 months)
- Quality of life by European Organization for Research and Treatment of Cancer- Cancer30 (EORTC-C30)(12 and 24 months)
研究者
Pamela Buchwald
associate professor, senior consultant surgeon
Skane University Hospital